Effectiveness of Deep Transcranial Magnetic Stimulation in Depression

Last updated: January 16, 2013
Sponsor: Douglas Mental Health University Institute
Overall Status: Completed

Phase

2/3

Condition

Depression (Major/severe)

Depression

Affective Disorders

Treatment

N/A

Clinical Study ID

NCT01409304
DTMS-ERB10/18-2011
  • Ages 18-60
  • All Genders

Study Summary

We intend to investigate whether deep transcranial magnetic stimulation (DTMS), a novel brain stimulation technique, is effective for treating major depression. We hypothesize that 4 weeks of DTMS will be associated with significant improvements in depressive and anxious symptoms without significant side effects.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Presence of a current major depressive disorder (according to the DSM-IV-TR) that hasnot improved after ≥ 1 but ≤ 5 adequate antidepressant trial(s) in the current episode

  • Baseline score ≥ 15 on the QIDS-C

  • Stable medication regimen (> 4 weeks)

Exclusion

Exclusion Criteria:

  • Psychotic features in the current episode

  • Lifetime history of psychotic disorders and/or bipolar I or II disorders

  • Substance or alcohol abuse/dependence in the past 6 months

  • Lifetime history of a major neurological disease (e.g., Parkinson's, stroke)

  • Uncontrolled medical disease (e.g., cardiovascular, renal)

  • Pregnancy and/or lactation

  • Presence of a specific contraindication for DTMS (e.g., personal history of epilepsy,metallic head implant)

  • Hearing loss

  • Personal history of abnormal brain MRI findings

Study Design

Total Participants: 18
Study Start date:
October 01, 2011
Estimated Completion Date:
December 31, 2012

Study Description

The aim of this pilot study is to assess, naturalistically, the effectiveness of deep transcranial magnetic stimulation (DTMS) in a sample of subjects with treatment-resistant depression. To do this, enrolled depressed outpatients will be assigned to receive 4 weeks of daily DTMS and will be evaluated at baseline and during week 5. We hypothesize that treatment with DTMS will be associated with significant clinical improvements in depressive and anxious symptoms, and will be well tolerated.

Connect with a study center

  • Neuromodulation Research Clinic, Douglas Mental Health University Institute

    Montreal, Quebec H4H1R3
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.